V
Valéria Rêgo Alves Pereira
Researcher at Oswaldo Cruz Foundation
Publications - 135
Citations - 2409
Valéria Rêgo Alves Pereira is an academic researcher from Oswaldo Cruz Foundation. The author has contributed to research in topics: Antigen & Trypanosoma cruzi. The author has an hindex of 26, co-authored 117 publications receiving 1950 citations.
Papers
More filters
Journal ArticleDOI
Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis.
Yone Vila Nova Cavalcanti,Maria Carolina Accioly Brelaz,Juliana Kelle de Andrade Lemoine Neves,José Candido Ferraz,Valéria Rêgo Alves Pereira +4 more
TL;DR: The knowledge about this responses based on the prevailing cytokine profile can help to elucidate the immune response related to the protection against M. tuberculosis, as well as support the survival of mycobacteria in the host.
Journal ArticleDOI
Induction of cancer cell death by apoptosis and slow release of 5-fluoracil from metal-organic frameworks Cu-BTC.
Flávia Raquel Santos Lucena,Larissa Cardoso Corrêa de Araújo,Maria D. Rodrigues,Teresinha Gonçalves da Silva,Valéria Rêgo Alves Pereira,Gardenia C.G. Militão,Danilo Augusto Ferreira Fontes,Pedro José Rolim-Neto,Fausthon F. da Silva,Silene Carneiro do Nascimento +9 more
TL;DR: In this article, the authors evaluated the mechanism associated with cytotoxic activity displayed by the drug 5-fluorouracil incorporated in Cu-BTC MOF and its slow delivery from the Cu-bitcoin MOF.
Journal ArticleDOI
2-Pyridyl thiazoles as novel anti-Trypanosoma cruzi agents: structural design, synthesis and pharmacological evaluation
Marcos Veríssimo de Oliveira Cardoso,Lucianna Rabelo Pessoa de Siqueira,Elany Barbosa da Silva,Lívia Bandeira Costa,Marcelo Zaldini Hernandes,Marcelo M. Rabello,Rafaela Salgado Ferreira,Luana Faria da Cruz,Diogo Rodrigo Magalhães Moreira,Valéria Rêgo Alves Pereira,Maria Carolina Accioly Brelaz de Castro,Paul V. Bernhardt,Ana Cristina Lima Leite +12 more
TL;DR: The present work reports on the synthesis, anti-Trypanosoma cruzi activities and docking studies of a novel series of 2-(pyridin-2-yl)-1,3-thiazoles derived from 2-pyridine thiosemicarbazone, which are potent cruzain inhibitors and showed excellent inhibition on the trypomastigote form of the parasite.
Journal ArticleDOI
Leishmaniases diagnosis: an update on the use of immunological and molecular tools
Milena de Paiva-Cavalcanti,Rayana Carla Silva de Morais,Rômulo Pessoa-e-Silva,Lays Adrianne Mendonça Trajano-Silva,Suênia da Cunha Gonçalves-de-Albuquerque,Diego H. C. Tavares,Maria Carolina Accioly Brelaz-de-Castro,Rafael de Freitas e Silva,Rafael de Freitas e Silva,Valéria Rêgo Alves Pereira +9 more
TL;DR: In this paper, the authors bring classical and current information about technological advances for the immunological and molecular leishmaniases diagnosis, their features, and applications, as well as their potential to clarify and minimize the present global situation of the diseases.
Journal ArticleDOI
Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
Diogo Rodrigo Magalhães Moreira,Salvana Priscylla Manso Costa,Marcelo Zaldini Hernandes,Marcelo M. Rabello,Gevanio Bezerra de Oliveira Filho,Cristiane Moutinho Lagos de Melo,Lucas F. Rocha,Carlos A. de Simone,Rafaela Salgado Ferreira,Jordana Rodrigues Barbosa Fradico,Cássio Santana Meira,Elisalva Teixeira Guimarães,Rajendra M. Srivastava,Valéria Rêgo Alves Pereira,Milena Botelho Pereira Soares,Ana Cristina Lima Leite +15 more
TL;DR: One high-efficacy trypanocidal compound was able to be identified, 2-minothiazolidin-4-one 18, which inhibited the activity of cruzain and the proliferation of epimastigotes and was cidal for trypomastigote but was not toxic for splenocytes.